Daniel C Malone

List of Publications by Year
in descending order

89 papers	2,810 citations	218677 26 h-index	189892 50 g-index
95 all docs	95 docs citations	95 times ranked	3359 citing authors

#	Article	IF	Citations
1	Amortization of gene replacement therapies: A health policy analysis exploring a mechanism for mitigating budget impact of high-cost treatments. Health Policy, 2022, 126, 49-59.	3.0	7
2	The potential for leveraging machine learning to filter medication alerts. Journal of the American Medical Informatics Association: JAMIA, 2022, 29, 891-899.	4.4	10
3	Real-world persistence, adherence, health care resource utilization, and costs in people with type 2 diabetes switching from a first-generation basal insulin to a second-generation (insulin glargine 300) Tj ETQq1 1 0.784314 rgBT /Overr... Pharmacy, 2022, , 1-12.	0.9	3
4	Changes in predicted opioid overdose risk over time in a state Medicaid program: a groupâ€based trajectory modeling analysis. Addiction, 2022, 117, 2254-2263.	3.3	2
5	Implementation of pharmacogenomic clinical decision support for health systems: a cost-utility analysis. Pharmacogenomics Journal, 2022, 22, 188-197.	2.0	4
6	Risk of tizanidine-induced adverse events after concomitant exposure to ciprofloxacin: A cohort study in the U.S.. American Journal of Emergency Medicine, 2022, 55, 147-151.	1.6	2
7	Coordinated use of Health Level 7 standards to support clinical decision support: Case study with shared decision making and drug-drug interactions. International Journal of Medical Informatics, 2022, 162, 104749.	3.3	5
8	Clinician Responses to a Clinical Decision Support Advisory for High Risk of Torsades de Pointes. Journal of the American Heart Association, 2022, 11, .	3.7	2
9	Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States. Advances in Therapy, 2022, 39, 3678-3695.	2.9	3
10	Overriding Drug-Drug Interaction Alerts in Clinical Decision Support Systems: A Scoping Review. Studies in Health Technology and Informatics, 2022, , .	0.3	3
11	Dualâ€trajectories of opioid and gabapentinoid use and risk of subsequent drug overdose among Medicare beneficiaries in the United States: a retrospective cohort study. Addiction, 2021, 116, 819-830.	3.3	26
12	Cost-effectiveness for KTE-X19 CAR T therapy for adult patients with relapsed/refractory mantle cell lymphoma in the United States. Journal of Medical Economics, 2021, 24, 421-431.	2.1	13
13	An updated cost-utility model for onasemnogene abeparvovec (ZolgensmaÂ®) in spinal muscular atrophy type 1 patients and comparison with evaluation by the Institute for Clinical and Effectiveness Review (ICER). Journal of Market Access & Health Policy, 2021, 9, 1889841.	1.5	27
14	Effectiveness and Efficiency of Non-drug Therapy Among Community-Dwelling Adults With Hypertension in China: A Protocol for Network Meta-Analysis and Cost-Effectiveness Analysis. Frontiers in Medicine, 2021, 8, 651559.	2.6	5
15	Evaluation of the cost-utility of a prescription digital therapeutic for the treatment of opioid use disorder. Postgraduate Medicine, 2021, 133, 421-427.	2.0	10
16	A Shared Decision-making Tool for Drug Interactions Between Warfarin and Nonsteroidal Anti-inflammatory Drugs: Design and Usability Study. JMIR Human Factors, 2021, 8, e28618.	2.0	5
17	Applying Clinical Decision Support Design Best Practices With the Practical Robust Implementation and Sustainability Model Versus Reliance on Commercially Available Clinical Decision Support Tools: Randomized Controlled Trial. JMIR Medical Informatics, 2021, 9, e24359.	2.6	13
18	Serum potassium changes due to concomitant ACEI/ARB and spironolactone therapy: A systematic review and meta-analysis. American Journal of Health-System Pharmacy, 2021, 78, 2245-2255.	1.0	5

#	Article	IF	Citations
19	Cost-effectiveness of once-daily vs twice-daily tacrolimus among Hispanic and Black kidney transplant recipients. Journal of Managed Care & Specialty Pharmacy, 2021, 27, 948-960.	0.9	0
20	Payer perceptions of the use of real-world evidence in oncology-based decision making. Journal of Managed Care & Specialty Pharmacy, 2021, 27, 1096-1105.	0.9	6
21	Real-world use and clinical outcomes after 24 weeks of treatment with a prescription digital therapeutic for opioid use disorder. Hospital Practice (1995), 2021, 49, 348-355.	1.0	11
22	The lifetime cost estimation of human papillomavirus-related diseases in China: a modeling study. Journal of Translational Internal Medicine, 2021, 9, 200-211.	2.5	7
23	Predicting Mortality Risk After a Hospital or Emergency Department Visit for Nonfatal Opioid Overdose. Journal of General Internal Medicine, 2021, 36, 908-915.	2.6	4
24	Cost-Effectiveness Analysis of a Prescription Digital Therapeutic for the Treatment of Opioid Use Disorder. Journal of Market Access & Health Policy, 2021, 9, 1966187.	1.5	6
25	Value of Active Warming Devices for Intraoperative Hypothermia Prevention—A Meta-Analysis and Cost-Benefit Analysis. International Journal of Environmental Research and Public Health, 2021, 18, 11360.	2.6	5
26	Five-year budget impact of a prescription digital therapeutic for patients with opioid use disorder. Expert Review of Pharmacoeconomics and Outcomes Research, 2021, , 1-9.	1.4	1
27	Trends, Patient and Prescriber Characteristics in Gabapentinoid Use in a Sample of United States Ambulatory Care Visits from 2003 to 2016. Journal of Clinical Medicine, 2020, 9, 83.	2.4	32
28	Testing the face validity and inter-rater agreement of a simple approach to drug-drug interaction evidence assessment. Journal of Biomedical Informatics, 2020, 101, 103355.	4.3	4
29	Characterizing health state utilities associated with Duchenne muscular dystrophy: a systematic review. Quality of Life Research, 2020, 29, 593-605.	3.1	19
30	Using machine learning to predict risk of incident opioid use disorder among fee-for-service Medicare beneficiaries: A prognostic study. PLoS ONE, 2020, 15, e0235981.	2.5	27
31	<p>Extent and Factors Associated with Adherence to Antidepressant Treatment During Acute and Continuation Phase Depression Treatment Among Older Adults with Dementia and Major Depressive Disorder</p>. Neuropsychiatric Disease and Treatment, 2020, Volume 16, 1433-1450.	2.2	2
32	Health economic evaluation of gene replacement therapies: methodological issues and recommendations. Journal of Market Access & Health Policy, 2020, 8, 1822666.	1.5	18
33	Health Outcomes Associated with Adherence to Antidepressant Use during Acute and Continuation Phases of Depression Treatment among Older Adults with Dementia and Major Depressive Disorder. Journal of Clinical Medicine, 2020, 9, 3358.	2.4	6
34	Cost-utility analysis of second-line anti-diabetic therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin. Current Medical Research and Opinion, 2020, 36, 1619-1626.	1.9	3
35	Risk of Bleeding with Exposure to Warfarin and Nonsteroidal Anti-Inflammatory Drugs: A Systematic Review and Meta-Analysis. Thrombosis and Haemostasis, 2020, 120, 1066-1074.	3.4	25
36	Criteria and Process for Initiating and Developing an ISPOR Good Practices Task Force Report. Value in Health, 2020, 23, 409-415.	0.3	23

#	ARTICLE	IF	CITATIONS
37	International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL Consortium. Lancet Oncology, The, 2020, 21, e83-e96.	10.7	180
38	Evidence of Clinically Meaningful Drug–Drug Interaction With Concomitant Use of Colchicine and Clarithromycin. Drug Safety, 2020, 43, 661-668.	3.2	13
39	Integrating the Practical Robust Implementation and Sustainability Model With Best Practices in Clinical Decision Support Design: Implementation Science Approach. Journal of Medical Internet Research, 2020, 22, e19676.	4.3	23
40	Is Real-World Evidence Used in P&T Monographs and Therapeutic Class Reviews?. Journal of Managed Care & Specialty Pharmacy, 2020, 26, 1604-1611.	0.9	4
41	Title is missing!. , 2020, 15, e0235981.		0
42	Title is missing!. , 2020, 15, e0235981.		0
43	Title is missing!. , 2020, 15, e0235981.		0
44	Title is missing!. , 2020, 15, e0235981.		0
45	Alzheimer's disease medication and risk of all‐cause mortality and all‐cause hospitalization: A retrospective cohort study. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 294-302.	3.7	22
46	Per-Prescription Drug Expenditure by Source of Payment and Income Level in the United States, 1997 to 2015. Value in Health, 2019, 22, 871-877.	0.3	2
47	Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patients. Journal of Market Access & Health Policy, 2019, 7, 1601484.	1.5	62
48	Evaluation of Machine-Learning Algorithms for Predicting Opioid Overdose Risk Among Medicare Beneficiaries With Opioid Prescriptions. JAMA Network Open, 2019, 2, e190968.	5.9	134
49	Extent and Predictors of Potentially Inappropriate Antidepressant Use Among Older Adults With Dementia and Major Depressive Disorder. American Journal of Geriatric Psychiatry, 2019, 27, 794-805.	1.2	8
50	Clinician preferences for computerised clinical decision support for medications in primary care: a focus group study. BMJ Health and Care Informatics, 2019, 26, e000015.	3.0	36
51	Identifying Common Methods Used by Drug Interaction Experts for Finding Evidence About Potential Drug-Drug Interactions: Web-Based Survey. Journal of Medical Internet Research, 2019, 21, e11182.	4.3	15
52	Implementation of Clinical Decision Support Services to Detect Potential Drug-Drug Interaction Using Clinical Quality Language. Studies in Health Technology and Informatics, 2019, 264, 724-728.	0.3	12
53	Economic impact of epilepsy and the cost of nonadherence to antiepileptic drugs in older Medicare beneficiaries. Epilepsy and Behavior, 2018, 80, 208-214.	1.7	18
54	An update on the prevalence and incidence of epilepsy among older adults. Epilepsy Research, 2018, 139, 107-112.	1.6	29

#	Article	IF	Citations
55	Real-World Evidence: Useful in the Real World of US Payer Decision Making? How? When? And What Studies?. Value in Health, 2018, 21, 326-333.	0.3	46
56	Effects on the medical revenue of comprehensive pricing reform in Chinese urban public hospitals after removing drug markups: case of Nanjing. Journal of Medical Economics, 2018, 21, 326-339.	2.1	17
57	Statistical analysis of patient-reported outcome data in randomised controlled trials of locally advanced and metastatic breast cancer: a systematic review. Lancet Oncology, The, 2018, 19, e459-e469.	10.7	66
58	Are US Health Insurers Efficient or Not?. Value in Health, 2018, 21, 398-399.	0.3	1
59	Moving forward toward standardizing analysis of quality of life data in randomized cancer clinical trials. Clinical Trials, 2018, 15, 624-630.	1.6	42
60	Is Real-World Evidence Used in P&T Monographs and Therapeutic Class Reviews?. Journal of Managed Care & Specialty Pharmacy, 2017, 23, 613-620.	0.9	16
61	Incidence of Exposure of Patients in the United States to Multiple Drugs for Which Pharmacogenomic Guidelines Are Available. PLoS ONE, 2016, 11, e0164972.	2.5	68
62	Predictors, Resource Utilization, and Short-term Costs of Laser Trabeculoplasty Versus Medication Management in Open-Angle Glaucoma. American Journal of Ophthalmology, 2016, 168, 78-85.	3.3	10
63	Prescribing attitudes, behaviors and opinions regarding metformin for patients with diabetes: a focus group study. Therapeutic Advances in Chronic Disease, 2016, 7, 220-228.	2.5	11
64	The impact of lower urinary tract symptoms on health-related quality of life among patients with multiple sclerosis. Neurourology and Urodynamics, 2016, 35, 48-54.	1.5	35
65	Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards. Lancet Oncology, The, 2016, 17, e510-e514.	10.7	158
66	Predictive modeling using a nationally representative database to identify patients at risk of developing microalbuminuria. International Urology and Nephrology, 2016, 48, 249-256.	1.4	2
67	Consensus Recommendations for Systematic Evaluation of Drug–Drug Interaction Evidence for Clinical Decision Support. Drug Safety, 2015, 38, 197-206.	3.2	96
68	Recommendations to improve the usability of drug-drug interaction clinical decision support alerts. Journal of the American Medical Informatics Association: JAMIA, 2015, 22, 1243-1250.	4.4	154
69	Towards a foundational representation of potential drug-drug interaction knowledge. CEUR Workshop Proceedings, 2014, 1309, 16-31.	2.3	3
70	Effect of an Educational Outreach Program on Prescribing Potential Drug-Drug Interactions. Journal of Managed Care Pharmacy, 2013, 19, 549-557.	2.2	10
71	Evaluation of a Wireless Handheld Medication Management Device in the Prevention of Drug-Drug Interactions in a Medicaid Population. Journal of Managed Care Pharmacy, 2012, 18, 33-45.	2.2	12
72	Ability of pharmacy clinical decision-support software to alert users about clinically important drug–drug interactions. Journal of the American Medical Informatics Association: JAMIA, 2011, 18, 32-37.	4.4	108

#	Article	IF	Citations
73	Burden of Alzheimer's disease and association with negative health outcomes. American Journal of Managed Care, 2009, 15, 481-8.	1.1	35
74	Pharmacist Workload and Pharmacy Characteristics Associated With the Dispensing of Potentially Clinically Important Drug-Drug Interactions. Medical Care, 2007, 45, 456-462.	2.4	98
75	Assessment of potential drug–drug interactions with a prescription claims database. American Journal of Health-System Pharmacy, 2005, 62, 1983-1991.	1.0	104
76	Concordance of Severity Ratings Provided in Four Drug Interaction Compendia. Journal of the American Pharmacists Association: JAPhA, 2004, 44, 136-141.	1.5	165
77	Identification of Serious Drug–Drug Interactions: Results of the Partnership to Prevent Drug–Drug Interactions. Journal of the American Pharmacists Association: JAPhA, 2004, 44, 142-151.	1.5	155
78	Interpreting the findings of the IMPROVE study. American Journal of Health-System Pharmacy, 2001, 58, 1330-1337.	1.0	42
79	Reduced Quality of Life in Veterans at Risk for Drug-Related Problems. Pharmacotherapy, 2001, 21, 1123-1129.	2.6	9
80	Economic burden of asthma: implications for outcomes and cost-effectiveness analyses. Expert Review of Pharmacoeconomics and Outcomes Research, 2001, 1, 177-186.	1.4	3
81	The Relationship between Drug Therapy Noncompliance and Patient Characteristics, Health–Related Quality of Life, and Health Care Costs. Pharmacotherapy, 2000, 20, 941-949.	2.6	102
82	An Economic Analysis of a Randomized, Controlled, Multicenter Study of Clinical Pharmacist Interventions for High-Risk Veterans: The IMPROVE Study. Pharmacotherapy, 2000, 20, 1149-1158.	2.6	74
83	Clinical and Economic Impact of Ambulatory Care Clinical Pharmacists in Management of Dyslipidemia in Older Adults: The IMPROVE Study. Pharmacotherapy, 2000, 20, 1508-1516.	2.6	125
84	Types of Interventions Made by Clinical Pharmacists in the IMPROVE Study. Pharmacotherapy, 2000, 20, 429-435.	2.6	49
85	Assessing the structure and process for providing pharmaceutical care in Veterans Affairs medical centers. American Journal of Health-System Pharmacy, 2000, 57, 29-39.	1.0	31
86	Characteristics of ambulatory care clinics and pharmacists in Veterans Affairs medical centers. American Journal of Health-System Pharmacy, 1998, 55, 68-72.	1.0	28
87	The IMPROVE study: Background and study design. American Journal of Health-System Pharmacy, 1998, 55, 62-67.	1.0	29
88	QTc Prolongation with the Use of Hydroxychloroquine and Concomitant Arrhythmogenic Medications: A Retrospective Study Using Electronic Health Records Data. Drugs - Real World Outcomes, 0, , .	1.6	0
89	A Disproportionality Analysis of Drug–Drug Interactions of Tizanidine and CYP1A2 Inhibitors from the FDA Adverse Event Reporting System (FAERS). Drug Safety, 0, , .	3.2	3